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Abstract
Interleukin 10 (IL-10) is important pleiotropic immunoregulatory cytokine which gene is located on chromosome 1 at 1q31-32. There are many 
genetic variants of IL-10 gene. However, the most studied are two dinucleotide repeats (microsatellites), IL10.G and IL10.R, located 1.2 kb and 4 kb 
upstream of the transcription start site and three single nucleotide polymorphisms (SNPs) -1082(G/A), -819(C/T) and -592(C/A). A large number of 
studies have shown that IL-10 gene polymorphisms are associated with different diseases and play an important role in pathophysiology and clini-
cal course of these diseases. This review summarizes published literature knowledge about the association of IL-10 polymorphisms and expression 
patterns with asthma, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, rheumatoid arthritis, tuberculosis and some neoplasms.
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Cytokines play an important role in modulation of 
the immune response. They are produced by im-
mune cells upon stimulation. By binding to specif-
ic receptors cytokines can either up-regulate acti-
vation, proliferation and differentiation of target 
cells, mediate or regulate immune reactions, inhib-
it the growth of cells, act cytotoxic, induce or in-
hibit the production of other cytokines. Cytokines 
are divided in two groups according to the func-
tion: anti-inflammatory and pro-inflammatory cy-
tokines. Lack of balance between pro- and anti-in-
flammatory cytokines disables proper function of 
immune system. In recent years, many researchers 
have noticed that differences in cytokine levels 
(high or low) are associated with certain allelic var-
iants of cytokine genes. These polymorphisms 
might play an important role in the pathophysiol-
ogy of various diseases.
Interleukin 10 (IL-10) is an important pleiotropic 
immunoregulatory cytokine mainly secreted by 
macrophages, but also by T helper 1 (Th1) and Th2 
lymphocytes, dendritic cells, cytotoxic T cells, B 
lymphocytes, monocytes and mast cells. Some 
studies have shown that it can be produced even 
by human carcinoma cell lines (1,2). IL-10 activity is 
mediated by the IL-10 receptor (IL-10R) which is a 
member of the class II cytokine receptor family. IL-
10 inhibits the capacity of monocytes and mac-
rophages to present antigen to T cells via an inhib-
itory effect on expression of major histocompati-
bility complex (MHC) class II, costimulatory mole-
cules such as CD80 (B7.1) and CD86 (B7.2) and 
therefore downregulates the expression of IL-1, IL-
6, IL-8, IL-12 and tumor necrosis factor – alpha 
(TNF-α). In B cells, IL-10 prevents apoptosis, en-
hances cell proliferation and has a role in immuno-
globulin (Ig) class switch.
The IL-10 gene is located on chromosome 1 at 
1q31-32, spans about 4.7 kb and contains four in-
trons and five exons (3). There are many genetic 
variants of IL-10 gene. However, the most studied 
are two dinucleotide repeats (microsatellites), 
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IL10.G and IL10.R, located 1.2 kb and 4 kb upstream 
of the transcription start site (4,5) and three single 
nucleotide polymorphisms (SNPs) -1082(G/A), 
-819(C/T) and -592(C/A) (6) which form three pre-
dominant haplotypes (GCC, ACC, ATA). Although 
endogenous and exogenous factors stimulate 
cells to produce IL-10, its secretion also depends 
on IL10.R, IL10.G and SNP polymorphisms in pro-
moter region. A summary of all IL-10 polymor-
phisms and haplotypes associated with diseases 
and their links to expression patterns are shown in 
Table 1. 
The pleiotropic role of IL-10 in immune system reg-
ulation coupled with polymorphic regulation of its 
expression, presents additional challenges for in-
terpretation, especially in the context of disease 
pathophysiology. The aim of this review was to 
present the most studied associations of IL-10 pol-
ymorphisms with susceptibility to selected diseas-
es and their severity. A literature search was con-
ducted using PubMed and SCOPUS from January 
2000 through to April 2014. Additional literature 
references were found by reviewing reference 
lists. Search was first performed using the search 
term “Interleukin 10 polymorphism” to discover 
which IL-10 polymorphisms and diseases were 
studied the most. Those were three single nucleo-
tide polymorphisms (SNPs): 1082(G/A), -819(C/T) 
and -592(C/A) in the promoter region which form 
three predominant haplotypes (GCC, ACC, ATA). 
The most studied diseases were asthma, systemic 
lupus erythematosus, psoriasis, inflammatory 
bowel disease, rheumatoid arthritis, tuberculosis 
and neoplasms. Further search was referred only 
to these diseases. Inclusion criteria for the review 
were publications limited to humans, well design 
case-control studies (sample size > 100, well-de-

















ATA at position 
-1082, -819, -592
asthma NM / / 272 / 307 Chatterjee et al. (10); 2005.
psoriasis NM / / 248 / 148 Kingo et al. (30); 2003.
-1082G
asthma NM / / 2215 / 2170 Hyun et al. (13); 2013.
systemic lupus 
erythematosus
NM / / 7948 / 11866 Liu et al. (24); 2013.
NM / / 2828 / 4008 Song et al. (25); 2013.
NM / / 2396 / 3653 Zhou et al. (26); 2013.
NM / / 2399 / 3483 Nath et al. (27); 2005.
Crohn’s disease NM / / 228 / 572 Fernandez et al. (32); 2005.
non-small cell lung 
cancer NM / / 154 / 205 Shih et al. (65); 2005.
diffuse large B-cell 
lymphoma
NM / / 199 / 112 Lech-Maranda et al. (66); 2004.
NM / / 1073 / 1738 Cao et al. (67); 2013.
cervical cancer NM / / 267 / 173 Matsumoto et al. (68); 2010.
oral cancer NM / / 144 / 141 Vairaktaris et al. (69); 2008.
-1082AA
rheumatoid 
arthritis NM / / 162 / 373 de Paz et al. (42); 2010.
asthma
NM / / 4716 / 5093 Zheng et al. (11); 2014.
NM / / 4478 / 4803 Nie et al. (12); 2012.
tuberculosis NM / / 5319 / 6723 Zhang et al. (54); 2011.
Table 1. Summary of IL-10 polymorphisms associated with diseases and their links to expression patterns.
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NM / / 3693 / 4574 Lv et al. (34); 2014.
NM / / 7704 / 9881 Zhu et al. (33); 2013.
tuberculosis
↑ blood protein 178 / 188 Ansari et al. (55); 2009.
NM / / 300 / 100 Meenakshi et al. (56); 2013.
rheumatoid 
arthritis NM / / 244 / 106
Paradowska-Gorycka et al. (43); 
2010.
-1082GA Crohn`s disease NM / / 7704 / 9881 Zhu et al. (33); 2013.
-592AA
asthma
NM / / 4716 / 5093 Zheng et al. (11); 2014.
NM / / 4478 / 4803 Nie et al. (12); 2012.
rheumatoid 
arthritis
NM / / 244 / 106 Paradowska-Gorycka et al. (43); 2010.
↓ blood protein 164 / 196 Ying et al. (46); 2011.
prostate cancer NM / / 509 / 382 Faupel-Badger et al. (71); 2008.




NM / / 244 / 106 Paradowska-Gorycka et al. (43); 2010.
↓ blood protein 164 / 196 Ying et al. (46); 2011.
diffuse large B-cell 
lymphoma NM / / 199 / 112 Lech-Maranda et al. (66); 2004.
-592C non-small cell lung cancer NM / / 154 / 205 Shih et al. (65); 2005.
-592CC tuberculosis NM / / 6559 / 7768 Liang et al. (57); 2014.
-819C
systemic lupus 
erythematosus NM / / 2828 / 4008 Song et al. (25); 2013.
inflammatory 
bowel disease NM / / 3693 / 4574 Lv et al. (34); 2014.
tuberculosis NM / / 6559 / 7768 Liang et al. (57); 2014.
non-small cell lung 
cancer NM / / 154 / 205 Shih et al. (65); 2005.
-819T diffuse large B-cell lymphoma NM / / 199 / 112 Lech-Maranda et al. (66); 2004.
-819TT
colon cancer ↓ tissue mRNA 160 / 160 Cacev et al. (72); 2008.
prostate cancer NM / / 509 / 382 Faupel-Badger et al. (71); 2008.
* NM - IL-10 concentration was not measured 
↑ - increased level of IL-10 in cases compared to controls.
↓ - decreased level of IL-10 in cases compared to controls.
ods, P < 0.05), meta-analysis (with stratification by 
age or ethnic origin if possible). No age limits were 
set. Power analysis has not been performed in any 
of the studies included in this review. All data are 
presented systematically and summarized in ta-
bles sorted according to the type of illness (IL-10 
polymorphism / haplotype associated with the 
disease, frequency of polymorphism / haplotype 
in cases compared to controls, population repre-
sented in the study).
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IL-10 in autoimmune and inflammatory 
diseases
Asthma
Asthma is a complex disorder in which both ge-
netic and environmental risk factors play an im-
portant role in pathogenesis of the disease. Pro-
inflammatory cytokines produced by Th2 cells 
have an important role in the chronic inflamma-
tion in asthma since they are responsible for IgE 
dysregulation (IL-4, IL-13), eosinophilia (IL-5, granu-
locyte-macrophage–colony stimulating factor 
(GM-CSF), IL-3), mast cell proliferation (IL-3, IL-9), 
IgE class switching (IL-4, IL-13) and hypersecretion 
of mucus and regulation of airway hypersensitivity 
(IL-13). Therefore, asthma is considered to be a Th2 
disease (7). The intrinsic physiologic mechanism 
for inhibiting pro-inflammatory cytokine synthesis 
is cytokine IL-10 (8). In healthy lungs the main 
sources of IL-10 are alveolar macrophages and cir-
culating monocytes (9). In bronchoalveolar lavage 
(BAL) alveolar macrophages represent more than 
80% of the cells present, while Th1 and Th2 lym-
phocytes, cytotoxic T cells, B lymphocytes and 
mast cells represent less than 10% of the cells (8).
An inverse association between severity of asthma 
and IL-10 concentration was shown by Borish et al. 
(8) who measured concentration of IL-10 in BAL in 
normal and asthmatic subjects using IL-10 en-
zyme-linked immunosorbent assay (ELISA). In BAL 
fluid of asthmatic patients IL-10 concentration was 
lower than in healthy controls (P < 0.01). Absence 
of IL-10 in asthma causes the continued secretion 
of pro-inflammatory cytokines such as IL-6, IL-5, IL-
4, TNF-α, GM-CSF and IL-1 which contribute to 
asthmatic airway inflammation.
Many candidate genes and SNPs have been stud-
ied and found out to be associated with asthma 
(Table 2). Chattarjee et al. (10), using both case-
control and family studies, showed that haplotype 
ATA at position -1082, -819, -592 was present more 
in asthmatics (N = 272) than in controls (N = 307) (P 
= 0.009) while haplotype ATC at position -1082, 
-819, -592 was more present in controls than in 
asthmatics (P = 0.012) in North Indians. IL-10 meta-
analysis involving 4716 asthmatic patients and 
5093 controls showed the association of -1082AA, 
-592AC and -592AA genotypes with asthma sus-
ceptibility in Asian adults (11). This association was 
also shown in meta-analysis involving 4478 asth-
matic patients and 4803 controls from different 
populations (12). Eleven studies involving 2215 
asthma patients and 2170 controls were included 
in a meta-analysis performed by Hyun et al. (13). 
Stratification by ethnicity indicated an association 
between the IL-10 -1082G allele and asthma in East 
Asians (P = 0.02). Stratification by age indicated an 
association between the IL-10 -1082G allele and 
asthma in adults (P = 0.02).
Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a complex 
autoimmune disease characterized by B lympho-
cyte hyperactivity and production of autoantibod-
Polymorphism
Frequency of 
polymorphism / haplotype 
in cases compared to 
controls
Population Reference
-1082AA ↑ meta-analysis Zheng et al. (11); 2014. Nie et al. (12); 2012.
-1082G ↓ East Asians Hyun et al. (13); 2013.
-592AA ↑ meta-analysis Zheng et al. (11); 2014. Nie et al. (12); 2012.
-592AC ↑ meta-analysis Zheng et al. (11); 2014. Nie et al. (12); 2012.
ATA at position -1082, 
-819, -592
↑ North Indians Chatterjee et al. (10); 2005.
↑ - increased frequency of polymorphism / haplotype in cases compared to controls.
↓ - decreased frequency of polymorphism / haplotype in cases compared to controls.
Table 2. Association of IL-10 polymorphism and haplotype with asthma.
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ies directed against double-stranded DNA, dys-
function of antigen-presenting cells (APC) and T 
lymphocytes. Increased production and decreased 
clearance of immune complexes leads to immune 
complex deposition in tissue and damage to mul-
tiple organ systems. IL-10 has the ability to induce 
autoantibody production by B lymphocytes sug-
gesting that IL-10 plays an important role in the 
pathogenesis of SLE (14). 
The major sources of IL-10 in patients with SLE are 
B cells and monocytes. IL-10 overproduction by B 
lymphocytes and monocytes was described for 
the first time by Llorente et al. (15). This observa-
tion was also confirmed by several other studies 
(16,17). Abnormal production of autoantibodies by 
B lymphocytes in patients with SLE is IL-10 de-
pendent and all related studies demonstrated that 
there is a positive correlation of serum IL-10 levels 
with disease activity (18-20). Interferons that are 
produced early in disease, as part of the immune 
response, have capacity to change IL-10 function 
from anti- to pro-inflammatory, so in this context 
IL-10 contributes to inflammation (21). In addition, 
immune complexes, that are produced in SLE, act-
ing through Fc gamma receptor II (FcgRII) stimu-
late IL-10 production from peripheral blood mono-
nuclear cells (PBMC), thus perpetuating the patho-
logical cycle. Rönnelid et al. (22) showed a signifi-
cant increase in IL-10 production in cell cultures in-
cubated with SLE sera, in comparison to cell cul-
tures incubated with control sera. This effect pro-
vides a possible explanation for the enhanced pro-
duction of IL-10 in patients with SLE, which leads 
to B cell hyperactivity, autoantibody production, 
immune complexes production, PBMC stimulation 
and again production of IL-10. Creation of this cy-
cle leads to increased deposition of immune com-
plexes in tissues and SLE associated pathology.
Numerous studies have investigated the associa-
tion between the -1082(G/A), -819(C/T) and -592(C/
A) polymorphisms and susceptibility to SLE, but 
the results were inconsistent. Therefore, a large 
number of meta-analysis in the last few years have 
been performed to assess the association be-
tween SLE and the IL-10 polymorphisms (Table 3). 
Twelve studies including 1765 cases and 2444 con-
trols were included in a meta-analysis performed 
by Wang et al. (23). The results indicated that there 
is a lack of association between the haplotype 
GCC at position -1082, -819, -592 and SLE risk, but 
another meta-analysis that included 7948 cases 
and 11866 controls has shown that the haplotype 
GCC at position -1082, -819, -592 is associated with 
SLE susceptibility same as -1082G allele (24). In me-
ta-analysis involving 2828 SLE patients and 4008 
controls (25), stratification by ethnicity indicated 
an association between the GCC haplotype and 
SLE in Europeans, IL-10 -819C allele and SLE in 
Asians, while an association between the IL-10 
-1082G allele and SLE in Europeans was also indi-
cated in meta-analysis (2396 cases and 3653 con-
trols) performed by Zhou et al. (26). Meta-analysis 
that included 2399 SLE patients and 3483 controls 
showed that -1082G allele is associated with SLE in 
Asians (27).
Psoriasis
Psoriasis is a cutaneous disorder characterized by 
overexpression of pro-inflammatory Th1 cytokines 
(IL-2, interferon-gamma (IFN-γ), TNF-α) while the 
level of expression of anti-inflammatory cytokines 
Polymorphism
Frequency of 




meta-analysis Liu et al. (24); 2013.
European Song et al. (25); 2013.
European Zhou et al. (26); 2013.
Asian Nath et al. (27); 2005.
-819C ↑ Asian Song et al. (25); 2013.
↑ - increased frequency of polymorphism / haplotype in cases compared to controls.
Table 3. Association of IL-10 polymorphism with systemic lupus erythematosus.
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(IL-4, IL-10) is low and insufficient to counterbal-
ance pro-inflammatory effects. Low levels of IL-10 
were observed in many studies (28,29) and it is be-
lieved that it plays a key role in the pathology and 
in the clinical course of psoriasis.
Polymorphisms of IL-10 promoter region in psoria-
sis were frequently investigated. In a study that in-
volved 248 patients with plaque type of psoriasis 
and 148 controls it was shown that ATA haplotype 
has a role in determining severity and course of 
plaque type of psoriasis since it is associated with 
persistent eruption (P < 0.01) (30). A meta-analysis 
involving Asian psoriasis patients (N = 1018) and 
controls (N = 1186) found significant association 
between psoriasis and the IL-10 -1082G allele (P = 
0.011) (31). 
Inflammatory bowel disease
Inflammatory bowel disease (IBD), which includes 
Crohn’s disease (CD) and ulcerative colitis (UC), is a 
chronic relapsing disease characterized by inflam-
mation of gastrointestinal tract, which leads to de-
struction of the mucosa. An important element in 
pathogenesis of IBD is disregulation of the intesti-
nal immune system. In the normal intestinal im-
mune system the balance of pro- and anti-inflam-
matory cytokines is essential for gut homeostasis. 
However, in IBD peripheral blood monocytes, in-
testinal monocytes and polymorphonuclear neu-
trophil granulocytes produce high amounts of 
pro-inflammatory cytokines (IL-6, TNF-α, IL-1β, IL-8) 
which leads to differentiation or proliferation of a 
variety of cells and tissue damage.
Genetic factors were also found to be associated 
with the development of UC and CD (Table 4). Fre-
quencies of IL10.G14 microsatellite allele and IL-10 
-1082G allele were higher in patients with CD (N = 
228) compared to patients with UC (N = 242) and 
controls (N = 572) (32). Zhu et al. (33) performed 
meta-analysis (7704 IBD patients and 9881 con-
trols) to estimate the association between -1082A/
G polymorphism in the IL-10 gene and IBD suscep-
tibility. The results demonstrated association be-
tween heterozygote genotypes -1082GA and 
-1082GG and CD. Another meta-analysis (3693 cas-
es and 4574 controls) showed association of 
-1082GG genotype and CD and -819C and IBD (34). 
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a chronic inflammato-
ry autoimmune disease that is characterized with 
chronic synovitis, which often leads to joint de-
struction. Expression of pro- and anti-inflammato-
ry cytokines in the synovial membrane of the in-
flamed joint is altered. Pro-inflammatory cy-
tokines, TNF-α and IL-1, are overproduced by mac-
rophages, synovial fibroblasts and neutrophils and 
play an important role in the process of chronic 
inflammation and joint destruction. 
Synovial fluid from patients with RA also contains 
detectable levels of anti-inflammatory cytokine IL-
10 but they are insufficient to counterbalance the 
effect of pro-inflammatory cytokines (35). The cel-
lular sources of IL-10 in the synovial tissue are mac-
rophages and T cells (35). In the presence of TNF-α 
and IL-1 expression of IL-10R on surface of dendrit-
ic cells in synovial fluid is low (36). Also, chronic ex-
Polymorphism
Frequency of 
polymorphism in cases 
compared to controls
Disease Population Reference
IL10 .G14 ↑ Crohn’s disease Spanish Fernandez et al. (32); 2005.
-1082G ↑ Crohn’s disease Spanish Fernandez et al. (32); 2005.
-1082GA ↑ Crohn’s disease Meta-analysis Zhu et al. (33); 2013.
-1082GG ↑ Crohn’s disease
Meta-analysis Lv et al. (34); 2014.
Meta-analysis Zhu et al. (33); 2013.
-819C ↑ Crohn’s disease, ulcerative colitis Meta-analysis Lv et al. (34); 2014.
↑ - increased frequency of polymorphism / haplotype in cases compared to controls.
Table 4. Association of IL-10 polymorphism with inflammatory bowel disease.
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posure of the pro-inflammatory cytokines (TNF-α 
and IL-1) modulates the IL-10 signalling and bioac-
tivity in synovial macrophages during chronic in-
flammation (37). RA patients showed significantly 
reduced IL-10 levels in serum in comparison to 
healthy donors, suggesting that IL-10 synthesis is 
depressed in RA (38). In addition, patients with ad-
vanced RA had the lowest values of IL-10 in serum 
(39). On the contrary, some studies have shown 
that concentration of IL-10 in sera of patients with 
RA is higher as compared to controls (40,41). Poly-
morphisms within the IL-10 gene promoter are as-
sociated with RA (Table 5). Frequency of genotype 
-1082AA was lower (P = 0.006) in RA patients (N = 
162) when compared to the control group (N = 
373) (42). In study performed by Paradowska-Gory-
cka et al. (43) it was found that frequency of geno-
type -1082GG was lower (P = 0.0001) while fre-
quency of genotype -1082GA was higher (P = 
0.009) in RA patients (N = 244) comparing to the 
control group (N = 106). A total of 1480 cases and 
1413 controls in 10 case-control studies were in-
cluded in meta-analysis performed by Zhang et al. 
(44). The results indicated that people with IL-10 
-1082GG and -1082GA genotype had a 25% lower 
risk of RA, when compared with the people with 
IL-10 -1082AA genotype. Meta-analysis (2647 RA 
patients and 3383 controls) showed association of 
the IL-10 -592C allele and the IL-10 -592CC geno-
type with RA (45). In Polish (43) and Chinese (46) 
RA patients frequency of -592AA genotype was 
significantly higher compared to controls, same as 
frequency of genotype -592CA and allele -592A, 
suggesting that allele A is associated with the low-
er expression of the IL-10 protein. 
Tuberculosis
Tuberculosis (TBC) is caused by Mycobacterium tu-
berculosis, an intracellular pathogen, which primar-
ily enters the human organism through respiratory 
tract and is phagocytised by macrophages and 
dendritic cells. Phagocytic cells undergo activation 
and maturation, which increases their potential to 
stimulate T cells. Cytokines released by activated T 
cells regulate differentiation, proliferation and ef-
fector functions of phagocytic cells with a purpose 
of removing intracellular pathogen and limiting 
disease. Th1 cytokines are produced during early 
stage of the infection while Th2 cytokines are pro-
duced during later stages. Balance between Th1 
and Th2 cytokines plays an important role in regu-
lating Mycobacterium tuberculosis infection. Com-
ponents of the Mycobacterium tuberculosis cell wall 
stimulate production of IL-10 by macrophages, but 
with a progression of inflammation, T cells be-
come a major source of IL-10 production. 
Studies have shown that IL-10 is associated with 
progression of disease caused by Mycobacterium 
tuberculosis (47,48). Increased IL-10 down-regulates 
Polymorphism / haplotype
Frequency of 
polymorphism / haplotype 
in cases compared to 
controls
Population Reference
-1082AA ↓ Spanish de Paz et al. (42); 2010.
-1082GG ↓ Polish Paradowska-Gorycka et al. (43); 2010.
-1082GA ↑ Polish Paradowska-Gorycka et al. (43); 2010.
-592CA ↑ Polish Paradowska-Gorycka et al. (43); 2010.
-592AA ↑
Polish Paradowska-Gorycka et al. (43); 2010.
Chinese Ying et al. (46); 2011.
-592A ↑
Polish Paradowska-Gorycka et al. (43); 2010.
Chinese Ying et al. (46); 2011.
↑ - increased frequency of polymorphism / haplotype in cases compared to controls.
↓ - decreased frequency of polymorphism / haplotype in cases compared to controls.
Table 5. Association of IL-10 polymorphism and haplotype with rheumatoid arthritis.
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secretion of important anti-mycobacterial mole-
cules: TNF-α and nitric oxide, expression of costim-
ulatory molecules and major histocompatibility 
complex (MHC) class II by macrophages and IFN-γ 
production by T cells (49,50). These findings sug-
gest that IL-10 is associated with promotion of 
pathological processes and Mycobacterium tuber-
culosis survival inside host macrophages during in-
fection. 
High concentration of IL-10 has been found in sera 
(51) and lungs (52) of patients with tuberculosis. 
Neutralization of endogenous IL-10 enhanced T 
cell IFN-γ production, expression of costimulatory 
molecules and accelerated the clearance of myco-
bacteria. Association of IL-10 polymorphism with 
tuberculosis is shown in Table 6. There were no 
statistically significant differences observed be-
tween patients with TBC and controls for the fre-
quency of IL-10 -1082 alleles or genotypes (P > 
0.05); however, a statistically significant difference 
in the frequency of IL-10 -1082GG genotype was 
found between patients with pulmonary and ex-
trapulmonary TBC (P = 0.003) (53). Genotype 
-1082AA (low IL-10 producer) is associated with re-
sistance to pulmonary tuberculosis (54) while gen-
otype -1082GG (high IL-10 producer) is associated 
with the risk of developing tuberculosis (55,56). 
Meta-analysis that included 31 studies with 6559 
cases and 7768 controls showed that three poly-
morphisms (-1082G/A, -819T/C and -592A/C) in the 
IL-10 gene were not associated with the risk of TBC 
in general population, but in the subgroup analy-
sis by ethnicity, IL-10 -1082AA and -1082AG geno-
types were associated with the TBC risk in Europe-
ans and Americans, while IL-10 -819C allele and 
-592CC and -592AC genotypes were significantly 
associated with the TBC risk in Asians (57).
IL-10 in melanoma and other malignancies
Cancer is a multifactorial disease, resulting from 
complex interactions between genetic and envi-
ronmental factors. Cytokines also have an impor-
tant role in cancer. They can either inhibit tumour 
development and progression if they are released 
in response to inflammation or they can induce tu-
mour invasion and metastasis if they inhibit apop-
tosis or promote growth. Since IL-10 has pleiotrop-
ic effects, its role and polymorphisms have been 
widely studied in different types of cancer. The 
role of IL-10 in cancer is best described in develop-
ment and progression of melanomas. 
Kriiger-Krasagakes et al. (58) investigated the ex-
pression of IL-10 mRNA in tissue specimens of pri-
mary malignant melanomas and melanoma me-
tastases as compared with normal skin. Their re-
sults showed that IL-10 mRNA was found in prima-
ry tumours tissues and metastases but not in nor-
mal skin. However, they could not distinguish 
which cells in the tumour tissue are producing IL-
10 mRNA, infiltrating cells (B cells, T cells and 
monocytes) or melanoma cells. Sato et al. (59) 
showed by cell separation experiments and intra-
cellular staining that the melanoma cells them-
selves are the major source of IL-10. They did not 
Polymorphism / haplotype
Frequency of 
polymorphism / haplotype 
in cases compared to 
controls
Population Reference
-819C ↑ Asian Liang et al. (57); 2014.
-592CC ↑ Asian Liang et al. (57); 2014.
-1082AA ↓ meta-analysis Zhang et al. (54); 2011.
-1082GG ↑
Pakistani Ansari et al. (55); 2009.
Indian Meenakshi et al. (56); 2013.
↑ - increased frequency of polymorphism / haplotype in cases compared to controls.
↓ - decreased frequency of polymorphism / haplotype in cases compared to controls.
Table 6. Association of IL-10 polymorphism and haplotype with tuberculosis.
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exclude the possibility that tumour-associated leu-
kocytes also produce IL-10 but suggested that 
their contribution would be minor.
IL-10 production by tumour cells increases as pri-
mary melanomas progress from melanoma in situ 
to invasive melanoma and metastatic melanoma 
(60). It is believed that IL-10 may have different 
roles during tumour development and progres-
sion. Melanoma cells express IL-10R (61) so IL-10 
acts as an autocrine growth factor. In the presence 
of IL-10 the proliferation of melanoma cells was in-
creased, the cells grew faster and the survival peri-
od of cells was prolonged. Melanoma cells also ex-
press gangliosides such as GD3 and GM3, which 
are important for tumour growth and metastasis. 
CD1 molecules, which are expressed by APC such 
as dendritic cells, recognize those gangliosides 
and destruct the cells. However, melanoma cells, 
by secreting IL-10, down-regulate CD1 molecules 
on infiltrating dendritic cells and escape the im-
mune response directed against the tumour (62). 
IL-10 also down-regulates human leukocyte anti-
gen (HLA) class I, HLA class II and intercellular ad-
hesion molecule 1 (ICAM-1) on human melanoma 
cells and therefore also the T-cell response. Apart 
from this immune-evading mechanism, it was 
demonstrated that IL-10 shows an anti-tumour ef-
fect via inhibition of angiogenesis (63), so its func-
tion in melanomas remains complex and still un-
clear. Presence of low producing ATA haplotype at 
position -1082, -819, -592 is associated with the 
susceptibility to melanoma (64). 
Association of IL-10 polymorphisms and other ma-
lignancies are shown in Table 7. IL-10 -1082G allele 
is associated with numerous other malignancies: 
non-small cell lung cancer (NSCLC) (65), diffuse 
large B-cell lymphoma (DLBCL) (66,67), cervical 
(68) and oral (69) cancer. In Chinese population al-
leles -819C and -592C were significantly associated 
with the occurrence of NSCLC (65). The frequen-
cies of -819T and -592A alleles were lower in French 
patients (N = 199) with DLBCL compared to con-
trols (N = 112) (66). Yu et al. (70) in a meta-analysis, 
based on 73 studies that included 15942 cases and 
22336 controls, found that -819CT genotype is a 




polymorphism / haplotype 




Chinese non-small cell lung cancer Shih et al. (65); 2005.
French diffuse large B-cell lymphoma Lech-Maranda et al. (66); 2004.
Japanese cervical cancer Matsumoto et al. (68); 2010.
Greek oral cancer Vairaktaris et al. (69); 2008.
Meta-analysis diffuse large B-cell lymphoma Cao et al. (67); 2013.
-819C ↑ Chinese non-small cell lung cancer Shih et al. (65); 2005.
-819T ↓ French diffuse large B-cell lymphoma Lech-Maranda et al. (66); 2004.
-819CT ↑ Meta-analysis cervical and ovarian cancer Yu et al. (70); 2013.
-819TT ↑
Finnish prostate cancer Faupel-Badger et al. (71); 2008.
Croatian colon cancer Cacev et al. (72); 2008.
-592C ↑ Chinese non-small cell lung cancer Shih et al. (65); 2005.
-592A ↓ French diffuse large B-cell lymphoma Lech-Maranda et al. (66); 2004.
-592AA ↑
Finnish prostate cancer Faupel-Badger et al. (71); 2008.
Croatian colon cancer Cacev et al. (72); 2008.
↑ - increased frequency of polymorphism / haplotype in cases compared to controls.
↓ - decreased frequency of polymorphism / haplotype in cases compared to controls.
Table 7. Association of IL-10 polymorphism and haplotype with other malignancies.
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cancer in Finish (71) and colon cancer in Croatian 
populations (72) are associated with low IL-10 
mRNA expression genotypes -819TT and -592AA. 
No significant differences in allele frequency or 
genotype distribution were observed for any of 
the IL-10 SNPs between patients with prostate can-
cer (N = 262) and control subjects (N = 270). How-
ever, significantly higher frequencies of -1082G (P 
= 0.005), -819C (P = 0.043) and -592C (P = 0.043) al-
lele and GCC haplotype (P = 0.008) were observed 
in early stage patients in comparison to advanced 
prostate cancer patients (73). 
Conclusion
Production of IL-10 is stimulated by various endog-
enous and exogenous factors, but certain allelic 
variants of IL-10 gene are also associated with dif-
ferences in IL-10 expression. Genetic association 
studies are performed to determine whether a ge-
netic variant is associated with the disease. IL-10 
has been shown to be a candidate gene in the 
pathophysiologic mechanism of autoimmune dis-
eases, inflammatory diseases and some neoplasms 
since it regulates both cellular and humoral immu-
nity. Three SNPs (-1082(G/A), -819(C/T), -592(C/A)) in 
the promoter region of the IL10 gene have been 
shown to alter IL-10 mRNA and protein levels. High 
expression of allele -1082G in patients compared 
to controls is associated with SLE, CD and neo-
plasms (non-small cell lung cancer, diffuse large B-
cell lymphoma, cervical and oral cancer) and pro-
motes development of pathological processes in 
these diseases. Genotype -1082AA is more preva-
lent in asthma, while in TBC and Crohn’s disease 
genotype -1082GG has higher frequency in cases 
compared to controls. Genotype -819TT is associ-
ated with low level of IL-10 in patients with colon 
cancer. In the presence of low IL-10 production al-
lele -592A and genotype -592AA in RA, expression 
of anti-inflammatory cytokine IL-10 is low and in-
sufficient to counterbalance the effect of pro-in-
flammatory cytokines. In patients with asthma, 
prostate and colon cancer frequency of low IL-10 
production genotype -592AA is higher compared 
to controls. However, it is necessary to perform ad-
ditional studies to fully understand the association 
of IL-10 polymorphisms with disease predisposi-
tion and underlying pathological processes.
Both overexpression (SLE, tuberculosis) as well as 
IL-10 deficiency (inflammatory bowel disease, pso-
riasis, asthma, rheumatoid arthritis) are likely to 
have a pathophysiological significance. Therefore, 
neutralization of the cytokine could be a promis-
ing approach to treat diseases from the first group, 
whereas application of IL-10 itself could be helpful 
for diseases from the second group. The role of IL-
10 as a therapeutic agent has been described in 
other reviews (74,75,76,77).
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